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Background: Increased activity or expression of integrin-linked kinase (ILK), which regulates cell adhesion, migration,
and proliferation, leads to oncogenesis. We identified the molecular basis for the regulation of ILK and its alternative
role in conferring ERK1/2/NF-κB-mediated growth advantages to gastric cancer cells.
Results: Inhibiting ILK with short hairpin RNA or T315, a putative ILK inhibitor, abolished NF-κB-mediated the growth in
the human gastric cancer cells AGS, SNU-1, MKN45, and GES-1. ILK stimulated Ras activity to activate the c-Raf/MEK1/2/
ERK1/2/ribosomal S6 kinase/inhibitor of κBα/NF-κB signaling by facilitating the formation of the IQ motif-containing
GTPase-activating protein 1 (IQGAP1)–Ras complex. Forced enzymatic ILK expression promoted cell growth by facilitating
ERK1/2/NF-κB signaling. PI3K activation or decreased PTEN expression prolonged ERK1/2 activation by protecting ILK
from proteasome-mediated degradation. C-terminus of heat shock cognate 70 interacting protein, an HSP90-associated
E3 ubiquitin ligase, mediated ILK ubiquitination to control PI3K- and HSP90-regulated ILK stabilization and signaling. In
addition to cell growth, the identified pathway promoted cell migration and reduced the sensitivity of gastric cancer cells
to the anticancer agents 5-fluorouracil and cisplatin. Additionally, exogenous administration of EGF as well as
overexpression of EGFR triggered ILK- and IQGAP1-regulated ERK1/2/NF-κB activation, cell growth, and migration.
Conclusion: An increase in ILK non-canonically promotes ERK1/2/NF-κB activation and leads to the growth of
gastric cancer cells.
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Integrin-linked kinase (ILK), a 59-kDa serine/threonine
kinase, directly interacts with the cytoplasmic domain of
β1 integrin [1]. ILK comprises three domains: N-terminal
ankyrin (ANK) repeats, a central pleckstrin homology
(PH)-like domain, and a C-terminal kinase domain [2,3].
Integrin-mediated cell–extracellular matrix (ECM) ad-
hesion or growth factors activate phosphatidylinositol
3-kinase (PI3K) to phosphorylate membrane-bound PI* Correspondence: cflin2014@tmu.edu.tw
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unless otherwise stated.4,5-bisphosphate (PIP2) and generate PI 3,4,5-triphos-
phate (PIP3), which binds to the PH-like domain of ILK
and activates ILK [4,5]. After ILK activation, the C-
terminal kinase domain of ILK can bind to various pro-
teins, including AKT, affixin, β-parvin, glycogen synthase
kinase (GSK)-3β, calponin homology-containing ILK-
binding protein, the 20-kDa regulatory light chains of my-
osin (LC20), the myosin-targeting subunit of myosin light
chain phosphatase (MYPT1), paxillin, α-NAC, and the
protein phosphatase inhibitors PHI-1, KEPI, and CPI-17
[2,3,6,7]. The N-terminal ANK repeats mediate the inter-
action of ILK with ILKAP, a protein phosphatase 2C fam-
ily member, and PINCH, an LIM domain-only adaptor
protein. ILK can be considered a PIP3-interacting proteintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tase and tensin homolog deleted on chromosome 10
(PTEN) [8,9]. PTEN suppresses tumors by dephosphory-
lating PIP3 [10,11].
ILK plays a vital role in regulating various cellular pro-
cesses, including proliferation, survival, migration, cell
cycle progression, and angiogenesis; increased activity
or expression of ILK leads to oncogenesis [2,3]. Besides
modulating its partner proteins for cellular processes,
ILK is hypothesized to be involved in an intracellular
signal transduction network. Mechanistically, ILK dir-
ectly phosphorylates AKT on Ser473 and GSK-3β on
Ser9 [4,9] to mediate β-catenin translocation and regu-
late AP-1 expression for tumor cell proliferation [12].
NF-κB activation is essential for ILK-mediated onco-
genic processes, such as anti-apoptotic activity [13],
survival promotion [14], epithelial–mesenchymal tran-
sition [15], cellular extension and resistance to apop-
tosis [16], angiogenesis [17], and migration, invasion,
and metastasis [18-20]. In addition, NF-κB activation is
required for the canonical regulation of IKKα and IKKß
by the ILK/AKT pathway. To trigger cell migration,
ILK can activate the small GTPases RAC and CDC42
[21]. Furthermore, ILK regulates ERK1/2 activation in
myogenic differentiation [22]. Increased expression of
microRNA-143 and microRNA-145, which target ILK,
inhibits AKT and ERK1/2 pathways [23]. However, the
molecular mechanism underlying ILK-mediated ERK1/
2 activation remains unknown.
The stimulation of cells by growth factors and cyto-
kines as well as cellular interaction with ECM increase
ILK activity [24]. In addition to the molecular regulation
of PI3K/PTEN by ILK, Aoyagi et al. identified ILK as a
new heat shock protein (HSP) 90 client protein and
found that pharmacologically inhibiting HSP90 resulted
in ILK degradation in a proteasome-dependent manner
[25]. Furthermore, the HSP90-associated E3 ubiquitin
ligase C-terminus of heat shock cognate 70 interacting
protein (CHIP) causes ILK degradation [26]. Hashiramoto
et al. demonstrated that HSP90 stabilized ILK and sus-
tained AKT and ERK1/2 activation [16]. Thus, we specu-
late a relationship between ILK stability and the activation
of its downstream kinases. Ras/MAPK pathway signaling
is essential for tumorigenesis [27]. Increased ILK expres-
sion is related to high-grade gastric cancer [28], prostate
cancer [29], and non-small cell lung cancer [30], although
cells in these cancers commonly harbor Ras mutations
[31-33]. Targeting ILK with siRNA decreases gastric can-
cer cell invasion, proliferation, and growth through an un-
known mechanism [34]. Regarding the possibility that ILK
acts upstream of NF-κB by regulating IKKα [13], which
has been implicated in gastric tumorigenesis [35], ILK
is speculated to activate cell growth through an NF-κB-
regulated pathway. Using gastric cancer cells (AGS,MKN45, and SNU-1), we studied the molecular regula-
tion of ILK and identified a non-canonical pathway of
ILK-regulated ERK1/2 activation for NF-κB-mediated
gastric cancer cell growth, migration, and survival
promotion.
Results
ILK activity and expression are essential for NF-κB-
mediated cell growth
Increased activity or expression of ILK enhances tumori-
genesis by promoting cell growth [6]. RNAi-based ILK si-
lencing attenuates gastric cancer cell growth [34], whereas
ILK overexpression is related to gastric tumorigenesis
[28]. In human gastric tumors and AGS-derived nodules
in BALB/c mice, Ki-67-positive proliferating cells coex-
pressed ILK as demonstrated by the fluorescence-based
immunostaining (Figure 1A) and AEC-based immuno-
staining (Additional file 1: Supplemental materials and
methods; Additional file 2: Figure S1) experiments. To
investigate the possible mechanisms underlying ILK-
mediated gastric cancer cell growth, several gastric epithe-
lial cell lines were characterized according to their different
cell growth rates, which were higher for the AGS and
SNU-1 cells and lower for the MKN45 and GES-1 cells,
and used in this study (Additional file 3: Figure S2A). Com-
pared with the MKN45 cells, the AGS and SNU-1 cells
also had elevated ILK expression (Additional file 3: Figure
S2B and S2C). A lentiviral-based shRNA was used to si-
lence ILK genetically in the AGS, SNU-1, MKN45, and
GES-1 gastric epithelial cells (Figure 1B, upper panel) as
well as in A549 and H1975 human lung adenocarcinoma
cells, HK-2 human renal proximal tubular epithelial cells,
and THP-1 human monocytic cells (Additional file 3:
Figure S2D). In these cells, ILK silencing significantly
(P <0.05) decreased cell growth (Figure 1B; Additional file
3: Figure S2E). Furthermore, treating cells with the ILK
inhibitor T315 [36] significantly (P <0.05) and dose-
dependently retarded cell growth (Figure 1C) without cyto-
toxicity (data not shown). Additionally, decreased colony
formation was observed in ILK-silenced AGS cells
(Additional file 3: Figure S2F). Thus, gene silencing
(Additional file 3: Figure S2G) and pharmacological
methods (Additional file 3: Figure S2H) to suppress ILK
activity or overexpression led to cell cycle arrest at the
G1 phase. These results show a growth-promoting role
of ILK.
To characterize the features of ILK-regulated cell growth,
NF-κB signaling was examined because ILK can act up-
stream of NF-κB by regulating IKKα [13]. By immu-
nostaining, the coexpression of ILK and phosphorylated
NF-κB (Ser536) was observed in human and mouse
gastric tissues (Figure 1D), and their coexpression sig-
nificantly (P <0.01) and positively correlated with the
number of proliferating cells, which is indicated by 55
Figure 1 ILK expression is necessary for cell growth and NF-κB activation. (A) Representative fluorescence-based immunohistochemical
staining shows the coexpression of ILK (green) and Ki-67 (red) in human gastric tumors and AGS-derived nodules in BALB/c mice. DAPI (blue) was
used for nuclear counterstaining. ILK+Ki-67+ cells in the immunofluorescently stained tissue sections are presented as dot-plots of a FACS-like
analysis by using TissueQuest software. The cells were calculated as the percentage and the cell number of the total cells (DAPI+ cells) per field.
(B) Western blot of ILK expression in cells transfected with shRNAs targeting ILK (shILK) or a control luciferase (shLuc). β-actin was used as an
internal control. WST-8-based assay shows the inhibition of cell growth in ILK-silenced cells. (C) The dose-dependent effect of the ILK inhibitor
T315 on the inhibition of AGS cell growth. (D) Representative fluorescence-based immunohistochemical staining shows the coexpression of ILK
(green) and phosphorylated NF-κB Ser536 (red) in human gastric tumors and AGS-derived nodules in mice. DAPI (blue) was used for nuclear
counterstaining. The dot-plots show the coexpression of ILK and NF-κB Ser536. (E) Logistic regression analysis showed a correlation between ILK,
phosphorylated NF-κB Ser536, and Ki-67 in 93 gastric cancer specimens tested. R-squared (R2) and P values are shown. (F) EMSA demonstrating
NF-κB activation. (G) Luciferase reporter assay shows the activation ratio of NF-κB to control Renilla luciferase in cells treated with the NF-κB
inhibitor CAPE (25 μg/mL). (H) Growth of 25 μg/mL CAPE-treated AGS cells. (I) NF-κB activation in shLuc- or shILK-transfected cells. (J) NF-κB
activation after 6 h of T315 treatment in AGS cells. For cell growth, colony formation, and luciferase activity, data are mean ± SD from three
independent experiments. *P <0.05, **P <0.01, and ***P <0.001 compared with Day 0 or relative control. #P <0.05, ##P <0.01, and ###P <0.001
compared with shLuc.
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(Figure 1E; Additional file 4: Figure S3). Immunostaining
for NF-κB nuclear translocation (Additional file 3: Figure
S2I), EMSA (Figure 1F), and promoter assays (Figure 1G)
confirmed the constitutive activation of NF-κB in the AGS
cells but not in the MKN45 cells. Treating cells with the
NF-κB inhibitor CAPE significantly (P <0.001) reduced NF-
κB activation (Figure 1G) and cell growth (Figure 1H).
Either ILK silencing (Figure 1I; Additional file 3: Figure S2J)
or T315 treatment (Figure 1J) significantly (P <0.05)
stopped NF-κB activity. These results demonstrated
that ILK is indispensable for cell growth in the cell lines
tested because it facilitates NF-κB activation in gastric
cancers.ILK regulates Ras activity by facilitating the complex of
IQGAP1–Ras to control MAPK-activated NF-κB
Because AGS cells harbor PIK3CA and KRAS mutations
[37], we examined possible regulatory effects of ILK on
the modulation of NF-κB activity by these 2 kinases [38].
Using a Human Phospho-MAPK Array Kit, we identified
10 kinases that were more highly expressed in the AGS
cells than in the MKN45 cells. These kinases mostly
acted downstream of the PI3K and MAPK signaling
pathways (Additional file 5: Figure S4A). By western
blotting, we confirmed an increased phosphorylation of
AKT, ERK1/2, and IκBα accompanied by IκBα degrad-
ation in the AGS cells (Figure 2A). The pharmacological
inhibition of c-Raf, MEK1/2, and PI3K significantly
(P <0.05) reduced cell growth (Figure 2B), IκBα phos-
phorylation (Ser32) and degradation (Figure 2C), and
NF-κB activity (Figure 2D), indicating that both PI3K-
and Ras-activating signaling pathways facilitated NF-κB
activation. The effects of ILK have been widely studied
because of its interactions with cell growth- and NF-κB-
associated AKT [4,9]. Surprisingly, ILK silencing did not
affect AKT and GSK-3β phosphorylation in the AGS and
SNU-1 cells but markedly reduced c-Raf and ERK1/2 ac-
tivation in all cells tested (Figure 2E; Additional file 5:
Figure S4B). Without AKT deactivation, we evaluated an
alternative pathway for activating NF-κB through a mech-
anism involving MAPK/p90RSK/IκBα signaling [38]. The
knockdown of ILK reduced the multiple phosphorylation
of RSK (Thr573, Thr359/Ser363, and Ser380) and IκBα
phosphorylation (Ser32) and increased IκBα accumulation
(Figure 2E). Inhibiting MEK1/2 caused similar effects
(Additional file 5: Figure S4C) and a cell cycle arrest at the
G1 phase (Additional file 5: Figure S4D). A Ras pull-
down assay revealed that inhibiting ILK caused Ras de-
activation without affecting the stability of the Ras protein
(Figure 2F). These findings demonstrated a potential
non-canonical pathway for ILK to modulate NF-κB by
regulating Ras/c-Raf/MEK1/2/ERK1/2/IκBα signaling.ILK can modify ERK1/2 activation under cell growth
and differentiation [22]; however, the molecular regulation
related to Ras signaling has not been documented [2,3].
The coexpression of ILK and phosphorylated ERK1/2
(Tyr202/Thr204) was demonstrated in human gastric
tumors and AGS-derived nodules in BALB/c mice
(Figure 2G). ILK interacts with IQGAP1 [7], a Ras
GTPase-activating-like protein that is dissimilar from
GAP, which transforms Ras to its inactive state. Because
IQGAP1 controls Ras/MAPK signaling, it is oncogenic
[39,40]. The expression of IQGAP family proteins was
unchanged in the AGS and MKN45 cells, even after
ILK silencing (Additional file 5: Figure S4E). However,
silencing oncogenic IQGAP1, but not IQGAP3, (Additional
file 5: Figure S4F–S4H) effectively inhibited c-Raf/
MEK1/2/ERK1/2/RSK signaling (Figure 2H), NF-κB activ-
ity, and cell growth (Figure 2I). By performing a coim-
munoprecipitation assay, we demonstrated a potential
complex harboring ILK, IQGAP1, and Ras (Figure 2J). Im-
munostaining confirmed that ILK was coexpressed at
levels similar to those of IQGAP1 and Ras (Figure 2K;
Additional file 6: Figure S5). Notably, silencing ILK dis-
rupted the IQGAP1–Ras complex (Figure 2L and 2M).
These results demonstrated that ILK facilitated the for-
mation of the IQGAP1–Ras complex to sustain Ras
activity.
Enzymatic ILK modulates the formation of the IQGAP1–
Ras complex and ERK1/2-mediated cell growth
Our findings showed that pharmacologically inhibiting
ILK decreased cell growth, indicating the essential role
of the enzymatic activity of ILK. Further inhibiting ILK
by the genetic approach disrupted IQGAP1-mediated
Ras signaling. Inhibiting ILK activity pharmacologically
with T315 (Figure 3A) or genetically by transfecting the
enzymatic mutant ILKA262V [41] (Figure 3B) also dis-
rupted the formation of the IQGAP1–Ras complex in
the AGS cells. Three truncated regions of ILK (Figure 3C)
were overexpressed in the MKN45 cells to identify the do-
main essential for sustaining the IQGAP1–Ras complex.
Coimmunoprecipitation assays demonstrated that overex-
pressed ILK constructs harboring PH and catalytic kinase
domain regions immunoprecipitated with IQGAP1 and
Ras (Figure 3D). Therefore, only kinase domain-containing
ILK activated ERK1/2 (Figure 3E). Compared with the full-
length ILK (ILK1–452), transfecting the kinase-dead mutant
ILKA262V did not activate ERK1/2 (Figure 3F). Ad-
ditional experiments demonstrated that only kinase
domain-containing ILK increased MEK1/2-regulated
NF-κB activation (Figure 3G) followed by MEK1/2- and
NF-κB-regulated cell growth (Figure 3H) in the MKN45
cells. These results showed that enzymatic ILK mediated
the formation of the IQGAP1–Ras complex to trigger
ERK1/2- and NF-κB-mediated cell growth.
Figure 2 ILK–IQGAP1–Ras complex sustains Ras activity to activate c-Raf/MEK1/2/ERK1/2/RSK/IκBα/NF-κB signaling. (A) Western blot of
the indicated proteins in AGS and MKN45 cells. β-actin was used as an internal control. AGS cells treated with c-Raf inhibitor GW5074, MEK1/2
inhibitors U0126 or PD98059, or PI3K inhibitor LY294002 for 48 h were evaluated for their growth (B), phosphorylation of IκBα at Ser32 (pIκBα)
and total protein (C), and NF-κB activation (D). (E) In shLuc- or shILK-transfected cells, western blots show the expression of the indicated proteins.
β-actin was used as an internal control. (F) Ras activation assay showing Ras activity and protein expression in shLuc- and shILK-transfected AGS cells.
(G) Representative fluorescence-based immunohistochemical staining showing the coexpression of ILK (green) and phosphorylated ERK1/2 Tyr202/
Thr204 (red) in human gastric tumors and AGS-derived nodules in BALB/c mice. DAPI (blue) was used for nuclear counterstaining. The dot-plots show
the coexpression of the indicated proteins. In control and IQGAP1 siRNA-transfected AGS cells at 48 h, the expression of the indicated proteins (H),
NF-κB activation, and cell growth (I) were shown. Protein lysates extracted from untreated AGS cells (J) or with shLuc and shILK transfection (L, M)
were immunoprecipitated (IP) with control IgG (C. IgG) or with antibodies against ILK, IQGAP1, and Ras. Immunoblots (IB) show the expression of ILK,
IQGAP1, and Ras. (K) Representative fluorescence-based immunohistochemical staining showing the coexpression of ILK (green), IQGAP1 (red), and Ras
(red) in AGS cells. DAPI (blue) was used for nuclear counterstaining. For proliferation and luciferase activity, data are mean ± SD from three independent
experiments. **P <0.01 and ***P <0.001 compared with control. Upright triangle, increased expression; inverted triangle, decreased expression.
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Figure 3 Enforced ILK expression facilitates cell growth by inducing ERK1/2/NF-κB activation. Protein lysates extracted from AGS cells treated
with T315 (A) or transfected with Myc-DDK-tagged mutant ILKA262V (B) were immunoprecipitated (IP) with antibodies against ILK. Immunoblots (IB)
show the expression of ILK, IQGAP1, and Ras. Plasmids based on pcDNA3.1-Flag-ILK containing full-length ILK (ILK1–452), fragment 171–452 (ILK171–452),
fragment 1–170 (ILK1–170) (C), or Myc-DDK-tagged mutant ILKA262V were transfected into MKN45 cells. (D) Coimmunoprecipitation of Flag with the
indicated proteins is shown by using western blotting. Compared with pcDNA3.1-Flag (Flag) only, western blots show the expression of phosphorylated
ERK1/2 at Tyr202/Thr204 (pERK1/2) (E, F). β-actin was used as an internal control. NF-κB activation (G) and cell growth (H) were also detected in the
absence or presence of PD98059 and CAPE. Data are mean ± SD from three independent experiments. **P <0.01 compared with control. ##P <0.01
compared with ILK1–452. Upright triangle, increased expression.
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ERK1/2/NF-κB activation by stabilizing ILK
Because ILK is dependent on PI3K-mediated PIP3 gener-
ation for its activation [4], growth factor- and integrin-
mediated PI3K activation or a PI3K mutation in the
AGS cells [37] could contribute to ILK expression and
activation. Compared with the growth of the MKN45
cells, the growth of the AGS cells was unaffected by ele-
vated IL-6 levels [42], and the expression of β1 and β3
integrins did not increase (Additional file 7: Figure S6).
We further confirmed that PIP3 generation was higher
in the PI3K-mutated AGS cells (Figure 4A). To explore
the relationships among the PI3K, ILK, and Ras signal-
ing pathways, the AGS cells were treated with the
MEK1/2, PI3K, ILK, or Ras inhibitor for different dura-
tions. At 6 h after treatment, T315 slightly inhibited
MEK1/2 and ERK1/2 phosphorylation (Additional file 8:
Figure S7). At 24 h after treatment, PI3K inhibitiondisrupted ILK expression, which was followed by MEK1/
2/ERK1/2 deactivation 24 h after treatment (Figure 4B).
However, Ras inhibition did not deactivate AKT or ILK
in the AGS cells, although Ras can mediate PI3K activa-
tion [27]. Similar to the ILK-silenced AGS cells, both
MKN45 and LY294002-stimulated AGS cells showed re-
duced Ras activity (Figure 4C). The translation inhibitor
cycloheximide facilitated LY294002-induced ILK downreg-
ulation (Figure 4D) and the proteasome inhibitor MG132
reversed the aforementioned effect and ERK1/2 inactiva-
tion (Figure 4E). The tumor suppressor phosphatase PTEN
negatively regulates PI3K/PDK1/AKT signaling [10,11] and
ILK activity [8,9], and the AGS cells exhibited a low ex-
pression of PTEN (Figure 2A) [43]. The forced expression
of PTEN in the AGS cells not only attenuated the con-
stitutive phosphorylation of PDK1, AKT, and PAK1 but
also inhibited ILK expression, ERK1/2 phosphorylation
(Figure 4F), and NF-κB activation (Figure 4G). These
Figure 4 PI3K activation and decreased PTEN expression facilitate ERK1/2/NF-κB activation through ILK stabilization. (A) A PIP3 Mass
ELISA Kit was used to determine PI3K activity by measuring the amount of PIP3 extracted from untreated AGS and MKN45 cells and from AGS
cells treated with LY294002 for 24 h. (B) AGS cells were treated with PD98059, LY294002, T315, or Ras inhibitor FTI-277 for the indicated times.
Western blots show the expression of the indicated proteins. β-actin was used as an internal control. (C) Ras activity was detected in AGS,
MKN45, and LY294002-treated AGS cells after 24 h. Western blots show the expression of the indicated proteins in AGS cells pretreated with the
translation inhibitor cycloheximide (CHX) (D) or proteasome inhibitor MG132 (E) for 0.5 h and then treated with LY294002 for 24 h. PTEN was
overexpressed in AGS cells by using pcDNA3.1-GFP-PTEN (PTEN). Western blots show the expression of the indicated proteins compared with
pcDNA3.1-GFP (Vector) transfection (F), and NF-κB activation (G) was also determined. For kinase and luciferase activity, data are mean ± SD from
three independent experiments. *P <0.05, **P <0.01, and ***P <0.001 compared with control. Upright triangle, increased expression; inverted
triangle, decreased expression.
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PTEN expression stabilize ILK to regulate ERK1/2/NF-
κB activation.
HSP90-associated E3 ligase CHIP negatively controls ILK
stabilization, ERK1/2/NF-κB activation, and cell growth
By further verifying the mechanism underlying ILK
destabilization, our results showed that AKT inhibitiondid not affect ILK stability, whereas PI3K inhibition
affected ILK stability (Additional file 9: Figure S8).
HSP90 was next investigated because it can cause ILK
degradation [25]. Similar to the results of PI3K inhib-
ition, shRNA-based (Figure 5A) or pharmacological
inhibition of HSP90 (Additional file 10: Figure S9A) de-
layed not only PDK1/AKT phosphorylation but also c-
Raf/MEK1/2/ERK1/2 activation after ILK degradation.
Figure 5 CHIP determines ILK destabilization, ERK1/2/NF-κB inactivation, and cell growth inhibition after PI3K/HSP90 inactivation. AGS
cells were transfected with shLuc or shHSP90 or pretreated with the HSP90 inhibitor 17-AAG (0.1 μM) for 48 h. Western blots show the expression
of the indicated proteins (A), and NF-κB activation (B) and cell growth (C) were also determined. (D) MG132 pretreatment (0.5 h) reversed ILK
expression and phosphorylated ERK1/2 at Tyr202/Thr204 (pERK1/2) in 17-AAG-treated AGS cells. (E) CHIP, cullin 4A, and cullin 4B were silenced in
AGS cells by shRNAs. shRNA-transfected cells were treated with LY294002 or 17-AAG for 24 h. Western blotting showed the expression of ILK and
phosphorylated ERK1/2 at Tyr202/Thr204 (pERK1/2) (F), and NF-κB activation (G) and cell growth (H) were also determined. (I) In shLuc- and
shCHIP-transfected AGS cells treated with LY294002, ILK was immunoprecipitated, and its ubiquitylation was probed. For western blot analysis,
β-actin was used as an internal control. For luciferase activity and cell growth, data are mean ± SD from three independent experiments. **P <0.01 and
***P <0.001 compared with control. ##P <0.01 and ###P <0.001 compared with shLuc or DMSO. NS: not significant. Upright triangle, increased expression;
inverted triangle, decreased expression.
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ing HSP90 by treatment with 17-AAG or the HDAC in-
hibitor SAHA, which traps HSP90 in an acetylated,
enzymatically inactive state, attenuated NF-κB activity
(Figure 5B; Additional file 10: Figure S9B) and cell growth
(Figure 5C). Cotreatment with MG132 rescued the effects
of 17-AAG (Figure 5D) and SAHA on ILK degradationand ERK1/2 inactivation (Additional file 10: Figure S9C).
In the MKN45 cells, treatment with MG132 increased
ILK expression, MEK1/2 and ERK1/2 phosphorylation
(Additional file 11: Figure S10), and NF-κB activation (data
not shown). Coimmunoprecipitation demonstrated the for-
mation of the HSP90–ILK complex (data not shown).
Using a lentiviral-based shRNA approach (Figure 5E),
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and cullin 4B [26,44,45], were examined for their roles in
ILK degradation. The results showed that only silencing
CHIP rescued ILK degradation and ERK1/2 inactivation
(Figure 5F), NF-κB deactivation (Figure 5G), and cell
growth inhibition (Figure 5H) after the pharmacological
inhibition of PI3K and HSP90. CHIP was required for
ILK ubiquitination in the LY294002-treated AGS cells
(Figure 5I). These results demonstrated that HSP90/
CHIP signaling regulates PI3K-mediated ILK stabilization
and ILK-regulated ERK1/2/NF-κB activation and thus fa-
cilitates cell growth.
PI3K/HSP90/CHIP/ILK/IQGAP1/ERK1/2/NF-κB signaling
contributes to cell migration and sensitivity to 5-FU and
cisplatin
Increased ILK activity or expression could regulate
oncogenic processes, including cell proliferation, migra-
tion, and survival [3,6]. We studied the potential involve-
ment of the identified PI3K/HSP90/CHIP/ILK/IQGAP1/
ERK1/2/NF-κB signaling pathway in cell growth advan-
tages. Compared with the MKN45 cells, the AGS cells
showed increased migratory activity; however, ILK or
IQGAP1 silencing significantly (P <0.001) abolished cell
migration (Additional file 12: Figure S11A). Pharmaco-
logically blocking PI3K/HSP90/ILK/MEK1/2/NF-κB sig-
naling in the AGS cells also significantly (P <0.001)
attenuated the migratory ability (Additional file 12:
Figure S11B), and CHIP knockdown considerably re-
versed the inhibitory effects caused by the inhibition of
PI3K and HSP90 (Figure 6A; Additional file 12: Figure
S11C). The anticancer agents 5-FU and cisplatin are
commonly used in the treatment of gastric cancers
[46]. Treating the AGS cells with 5-FU or cisplatin,
particularly after ILK or IQGAP1 silencing, caused in-
creased susceptibility to apoptosis (Figure 6B). T315
increased the sensitivity of the AGS cells to 5-FU and
cisplatin (Additional file 12: Figure S11D). Pharmaco-
logically inhibiting PI3K/HSP90/ILK/MEK1/2/NF-κB
signaling also sensitized the AGS cells to 5-FU-induced
apoptosis (Figure 6C), whereas CHIP silencing retarded the
synergistic effects of LY294002 and 17-AAG on 5-FU-
induced apoptosis (Figure 6D). In contrast, the overexpres-
sion of ILK containing a catalytic kinase domain, including
ILK1–452 and ILK171–452, enhanced MEK1/2/NF-κB-regu-
lated cell migration (Figure 6E) and cell survival after treat-
ment with 5-FU (Figure 6F). These results indicated the
common effects of ILK and IQGAP1 on ERK1/2/NF-κB
activation for cell migration and survival.
EGFR signaling regulates ILK/IQGAP1 to activate ERK1/2,
NF-κB, and cell migration and proliferation
To verify the role of ILK/IQGAP1-mediated ERK1/2 and
NF-κB activation, we examined EGF/EGFR signaling aspreviously described [47,48]. ILK or IQGAP1 silencing
partially eliminated the exogenous EGF-induced ERK1/2
and AKT phosphorylation in the AGS (Figure 7A) and
A549 cells (Additional file 13: Figure S12A). However,
IQGAP1 silencing attenuated EGF-activated ERK1/2
but not EGF-activated AKT, suggesting an IQGAP1-
independent AKT activation. ERK1/2 phosphorylation
through multiple stimuli, including hydrogen peroxide
(Additional file 13: Figure S12B) and Helicobacter pylori
infection (Additional file 13: Figure S12C) [49-51], was
also abolished in the ILK-silenced cells. Silencing ILK
or IQGAP1 caused a significant (P <0.001) decrease in
EGF-induced NF-κB activation (Figure 7B), and cell
growth (Figure 7C) and migration (Figure 7D). The
wild-type and the constitutively active form of EGFR
mutated at domain VIII [48,52] were transfected into
the MKN45 cells, which were then treated with or with-
out EGF. ILK overexpression was accompanied by
ERK1/2 and AKT activation; however, inhibiting PI3K
and HSP90 decreased not only ILK expression but also
ERK1/2 and AKT activation (Figure 7E). These findings
demonstrated that both ILK and IQGAP1 are required
for EGF/EGFR-triggered ERK1/2/NF-κB activation and
cell growth advantages and that ILK expression can be
positively regulated by EGF/EGFR/PI3K/HSP90 signaling.
Discussion
By using genetic and pharmacological approaches, we
confirmed the proliferation-promoting role of ILK in vitro
in gastric cancer cells. The function of ILK is highly re-
lated to NF-κB activation. An in vivo model of gastric can-
cer in mice showed the essential role of ILK in tumor
growth [34], and increased ILK [28] and NF-κB [35] activ-
ity or expression is related to gastric tumorigenesis. Al-
though the potent mechanisms for ILK-regulated cell
proliferation have been previously documented [6], we
further investigated the molecular basis of ILK-mediated
gastric cancer cell growth, which is related to NF-κB acti-
vation. To the best of our knowledge, clinical observations
in this study indicated a positive correlation between ILK
expression, NF-κB activation, and cell proliferation in gas-
tric cancers. Protection from apoptosis [13] and the stimu-
lation of cell proliferation are oncogenic effects of ILK
that are generally achieved by facilitating NF-κB activa-
tion. Based on these rationales, the molecular regulation
of the ILK/NF-κB pathway was examined. According to
the present study results (summarized in Figure 8), in-
creased ILK activity or expression, which is controlled by
PI3K/HSP90-mediated protein stabilization, triggers a
non-canonical pathway of IQGAP/Ras/c-Raf/MEK1/2/
ERK1/2/RSK/NF-κB signaling to stimulate cell growth,
migration, and survival.
Aberrant ILK is involved in tumorigenesis, and it is spec-
ulated that ILK canonically stimulates AKT to promote
Figure 6 PI3K/HSP90/CHIP/ILK/ERK1/2/NF-κB signaling determines cell migration and controls susceptibility to the anticancer agents
5-FU and cisplatin. (A) Migration activity was tested in shLuc- or shCHIP-transfected AGS cells treated with LY294002 (25 μM) and 17-AAG
(0.2 μM) for 12 h. shLuc, control siRNA, or DMSO were used as negative controls. The numbers of migrated cells in the observed field are shown.
PI staining followed by flow cytometry analysis showed 5-FU- or cisplatin-induced apoptosis for 2 days in shILK- or siIQGAP1-transfected AGS cells
(B), AGS cells pretreated with the indicated inhibitors for 0.5 h (C), and shLuc- or shCHIP-transfected AGS cells treated with LY294002 or 17-AAG
(D). shLuc, control siRNA, or DMSO were used as negative controls. Plasmids based on pcDNA3.1-Flag-ILK containing full-length ILK (ILK1–452),
fragment 171–452 (ILK171–452), or fragment 1–170 (ILK1–170) were transfected into MKN45 cells. Compared with pcDNA3.1-Flag (Flag) only, cell
migration (E) and apoptosis induced by 5-FU (5 μM) (F) were detected in the absence or presence of PD98059 and CAPE. Data are mean ± SD
from three independent experiments. *P <0.05, **P <0.01 and ***P <0.001 compared with control. #P <0.05, ##P <0.01, and ###P <0.001 compared
with control. NS: not significant.
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apoptosis [13] and survival [14]. In tumorigenesis, NF-
κB can promote survival and proliferation, angiogenesis,
adhesion/invasion/metastasis, and inflammation. However,
the mechanisms underlying NF-κB activation in cancer
cells are multifaceted; both AKT and MAPKs are crucial
for NF-κB activation [38]. Of note, AGS cells have mutated
PIK3CA and KRAS [37]. Inhibiting PI3K and Ras activity
attenuated NF-κB activation. We therefore hypothesized arole for ILK to canonically or non-canonically act upstream
of AKT and ERK1/2, respectively. ILK-mediated AKT
phosphorylation at Ser473 was confirmed in lung adeno-
carcinoma A549 cells but not in gastric cancer cells. Sur-
prisingly, ILK silencing effectively negatively affected
ERK1/2 activation in all cells tested. In addition to the kin-
ase activity of ILK, scaffold functions of ILK associated
with intracellular molecules also need further investigation
to verify its roles in regulating AKT and ERK1/2 signaling.
Figure 7 ILK and IQGAP1 facilitate EGF/EGFR-induced NF-κB activation and cell growth and migration, and activated EGFR increases
ILK expression. (A) Western blots showing ERK1/2 phosphorylation at Tyr202/Thr204 (pERK1/2) and AKT phosphorylation at Ser473 (pAKT S) in
shILK- or siIQGAP1-transfected AGS cells treated with EGF for 1 h. shLuc and control siRNA were used as negative controls. β-actin was used as an
internal control. Furthermore, in these cells, NF-κB activation (B), cell growth (C), and migration (D) were detected. Data are mean ± SD from three
independent experiments. **P <0.01 and ***P <0.001 compared with negative control. ###P <0.001 compared with shLuc or control siRNA. (E) In
EGFR WT-transfected and EGFR VIII-transfected MKN45 cells treated with or without EGF for 1 h plus LY294002 or 17-AAG 24 h posttreatment,
western blots show the expression of ILK, phosphorylated ERK1/2 at Tyr202/Thr204 (pERK1/2), and phosphorylated AKT at Ser473 (pAKT S). β-actin
was used as an internal control. Upright triangle, increased expression; inverted triangle, decreased expression.
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involving MAPK/p90RSK/IκBα signaling [38]; similarly, we
demonstrated that this pathway was required for ILK-
mediated NF-κB activation in gastric cancer cells. ILK has
a possible upstream role in ERK1/2 activation [16,22,23,48],
but no rational mechanisms exist for examining this
regulation [2,3].
An emerging and widely demonstrated role for IQGAP1
is its control over diverse biological functions by interact-
ing with various cellular factors [53]. For MAPK signaling,
IQGAP1 can directly regulate Ras/ERK1/2 activation dur-
ing tumorigenesis [39,40]. Ras is a small GTPase that can
hydrolyze GTP into GDP in a GTP-bound protein to in-
activate the protein, a process accelerated by GAPs, and
this process can be reversed with a guanine nucleotide ex-
change factor to reactivate the Raf/MAPK pathway [27].
IQGAP is a Rho–GTP-binding protein and has a region
similar to that of Ras GAP. However, IQGAP has no GAPfunction but can stabilize the GTP-bound protein in an
activated state [54,55]. A global analysis of the ILK inter-
actome has shown a strong ILK–IQGAP1 interaction [7];
however, no studies have illustrated the axis of ILK/
IQGAP1/Ras signaling. Wickstrom et al. demonstrated an
ILK–IQGAP1 association through the non-ANK repeats
of ILK and the IQ motif of IQGAP1 for facilitating integ-
rin signaling [56]. To our knowledge, the present study is
the first to show that increased or decreased activity or
expression of ILK did not affect IQGAP1 expression,
although silencing ILK disrupted the IQGAP1–Ras inter-
action. These three proteins formed a novel complex
around the cell membrane, particularly in cell–cell junc-
tions. Regarding IQGAP1 sustaining Ras activity in gastric
cancer cells, IQGAP1 but not IQGAP3 mediated cell
growth through an ERK1/2-regulated NF-κB activation
pathway. The present study reveals a novel axis of ILK/
IQGAP1 for Ras/ERK1/2 signaling; however its cellular
Figure 8 A hypothetical model for PI3K/HSP90-regulated ILK, followed by ILK-mediated IQGAP1/Ras/c-Raf/MEK1/2/ERK1/2/RSK/NF-κB
activation in cell growth, migration, and survival.
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expression of IQGAP1 is related to poor prognosis in gas-
tric cancers [57]. The formation of an ILK–IQGAP1 com-
plex may have multiple biological effects; IQGAP1 has
been implicated in diverse cellular functions through a
mechanism involving the interaction of cytoskeletal com-
ponents, small GTPases, kinases, and receptors [53].
Besides using the genetic approach, pharmacologically
inhibiting ILK with T315 or an ILK kinase-dead muta-
tion (ILKA262V) abolished the IQGAP1–Ras interaction
and thus deactivated ERK1/2. The enzymatic activity of
ILK is speculated to be crucial for the axis of ILK/
IQGAP1/Ras signaling. Further results showed the im-
portance of the PH-like domain and the kinase domain
in mediating the formation of ILK/IQGAP1 complex as
well as ERK1/2 activation, NF-κB activation, and cell
growth. The mechanism underlying the ILK-mediated
IQGAP1–Ras interaction is unknown; ILK phosphory-
lates its substrates as well as acts as an adaptor for pro-
tein–protein interactions [2,3]. Together with the findings
that the non-ANK repeats of ILK are required for binding
with the IQ domain of IQGAP1 [53,56], it is reasonable
to hypothesize that ILK initiates the phosphorylation of
the IQGAP1–Ras complex and/or that ILK confers an
adaptor-mediated interaction for this complex.
Although increased ILK expression contributes to
tumorigenesis, the mechanisms for ILK overexpression
remain unknown. ILK upregulation and activation are
related to β1 integrin signaling [1], and integrins may
regulate gastric tumorigenesis, particularly by modulatingadhesion and metastasis [58,59]. Thus, integrin overex-
pression causes ILK upregulation and activation. However,
in the gastric cancer cell lines AGS and MKN45 that we
tested, there were no differences in the expression or acti-
vation of β1 or β3 integrin. In addition to integrin signal-
ing, growth factors generally activate PI3K for cell growth
advantages. The expression of cell growth-associated IL-6
is higher in the AGS cells than in the MKN45 cells; how-
ever, its potential role in gastric cancer cell proliferation
has been excluded. In addition to PIK3CA mutations [37],
growth factors involved in regulating ILK expression need
further investigation.
Surprisingly, pharmacologically inhibiting PI3K de-
creased ILK expression along with ERK1/2 deactivation.
This result indicates an upstream role for PI3K-regulated
ILK stabilization linked to Ras/ERK1/2 signaling. In the
AGS cells, ILK overexpression may result from a natural
mutation in PIK3CA that generates PIP3 to stabilize ILK
expression. The most important finding in this study is
the mechanism of ILK-dependent ERK1/2 activation
demonstrated in the AGS cells, although these cells har-
bor PI3CA and KRAS mutations [37]. ILK may be required
to sustain Ras activity, although Ras is automatically acti-
vated. The PH-like domain is essential for ILK to interact
with PIP3 [4]. Once PI3K-driven PIP3 generation mediates
ILK recruitment, ILK signaling can be initiated after
protein stabilization. It is speculated that aberrant PI3K
activation can cause ILK upregulation. The level of
PTEN, a tumor suppressor related to PIP3 downregula-
tion, is markedly decreased in several cancers, including
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cells effectively abolished both AKT and ERK activation
and decreased ILK expression. PI3K/PTEN/PIP3-medi-
ated ILK stabilization is therefore important for ERK1/
2 activation.
PDK1 activates PAK1 [60], and PAK1 phosphorylates
ILK [61]. Here, the pharmacological inhibition of PI3K
inhibited PDK1 and PAK1 activation (Additional file 14:
Figure S13A); however, PAK1 knockdown did not alter
ILK expression but decreased c-Raf/ERK1/2 phosphoryl-
ation, NF-κB activation, and cell growth (Additional file 14:
Figure S13B–13D). These results indicated that PI3K-
controlled PAK1 does not contribute to ILK expression.
HSP90 is a chaperone that associates with client proteins
[62-65]. HSP90 regulates ILK stability [25] through an
interaction at amino acids 377–406 within the kinase do-
main of ILK. HSP90 can maintain the tumor-like character
of rheumatoid synovial cells by stabilizing ILK, ERK, and
AKT [16]. However, the potential regulation of ILK/ERK/
AKT signaling by HSP90 remains undetermined. Our
study further demonstrated that the HSP90-associated E3
ligase CHIP was required for ILK stabilization, whereas
inhibiting PI3K and HSP90 caused CHIP-proteasome-
mediated ILK degradation. Radovanac et al. demonstrated
that ILK stability is negatively regulated by CHIP ubiquiti-
nation in fibroblasts when HSP90 is inhibited [26]. The
molecular stabilization of ILK by HSP90 and CHIP re-
mains unclear, but HSP90 interacts with the kinase domain
of ILK [25,26], and CHIP-mediated ubiquitylation occurs
at the ANK repeats of ILK [26]. CHIP regulates ILK stabil-
ity in conjunction with others, and this regulation is im-
portant for ILK-regulated ERK1/2 and NF-κB activation
and cell growth. Regarding the multiple oncogenic effects
of ILK, the results of this study and those of previous
studies reveal the molecular mechanism of ILK stabilization
and expression; furthermore, we showed that ILK promotes
cancer cell growth, migration, and survival responses
through ERK1/2-regulated NF-κB activation.
The limitation of this study is that the changes ob-
served were in the AGS cells, which have PIK3CA and
KRAS mutations [37] and decreased PTEN expression.
To confirm the finding that ILK facilitates ERK1/2 acti-
vation in response to physiological and pathological sti-
muli, we showed that hydrogen peroxide and H. pylori
infection caused ILK-regulated ERK1/2 activation. In
addition, the exogenous administration of EGF confirmed
the requirement of ILK and IQGAP1 in EGF-induced
ERK1/2 activation, NF-κB activation, cell growth, and mi-
gration [47,48]. Crosstalk between EGFR and integrins fa-
cilitates gastric cancer cell invasion and proliferation [66].
Moreover, the overexpression of WT EGFR and EGFR
mutated at domain VIII may induce PI3K/HSP90-regu-
lated ILK stabilization followed by ERK1/2 activation
[48,52]. Regarding the critical role of Ras/ERK1/2 in cellgrowth advantages [27], the aforementioned results eluci-
date the significance of ILK in cell growth advantages, at
least in gastric cancers, through a non-canonical mechan-
ism involving the facilitation of ERK1/2 activation.
Conclusion
Based on the finding that PI3K/PTEN/HSP90-regulated
ILK upregulation induces non-canonical IQGAP1/Ras/
ERK1/2-mediated NF-κB activation and growth advan-
tages in gastric cancer cells, targeting this pathway may
be beneficial when used in combination with other anti-
cancer agents. Our hypothesis requires further in vivo
investigation with an appropriate animal model.
Materials
Chemicals and antibodies
The ILK inhibitor T315 was a gift from Dr. Ching-Shih
Chen, College of Pharmacy, The Ohio State University
[36]. The NF-κB inhibitor caffeic acid phenethyl ester
(CAPE); c-Raf inhibitor GW5074; MEK inhibitors U0126
and PD98059; PI3K inhibitor 2-(4-morpholinyl)-8-phenyl-
4H-1-benzopyran-4-one hydrochloride (LY294002); transla-
tion inhibitor cycloheximide; proteasome inhibitor MG132;
Ras inhibitor FTI-277; HSP90 inhibitor 17-AAG; 5-
fluorouracil (5-FU); cisplatin; dimethyl sulfoxide (DMSO);
4,6-diamidino-2-phenylindole (DAPI); and propidium iod-
ide (PI) were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Antibodies against phosphorylated AKT at
Ser473 (pAKT S), phosphorylated AKT at Thr308 (pAKT
T), AKT, phosphorylated GSK-3α/β at Ser21/Ser9 (pGSK-
3α/β), GSK-3α/β, phosphorylated PDK1 at Ser241 (pPDK1),
PDK1, phosphorylated PAK1 at Thr423 (pPAK1), PAK1,
phosphorylated c-Raf at Ser338 (pc-Raf), c-Raf, phosphory-
lated MEK1/2 at Ser217/Ser221 (pMEK1/2), MEK1/2,
phosphorylated ERK1/2 at Thr202/Tyr204 (pERK1/2),
ERK1/2, phosphorylated p90RSK at Thr573 (pRSK T),
phosphorylated p90RSK at Thr359/Ser363 (pRSK T/S),
phosphorylated p90RSK at Ser380 (pRSK S), RSK, phos-
phorylated IκBα at Ser32 (pIκBα), IκBα, NF-κB, PTEN,
HSP90, CHIP, cullin-4A/4B, ubiquitin, and anti-EGFP were
purchased from Cell Signaling Technology (Beverly, MA,
USA). Anti-ILK, anti-phosphorylated NF-κB at Ser536
(pNF-κB), anti-Ras, and anti-IQGAP1, anti-IQGAP2,
and anti-IQGAP3 antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Antibodies against Ki-67 and NF-κB were purchased
from Abcam (Cambridge, MA, USA). Mouse monoclo-
nal antibodies specific for β-actin and FLAG were pur-
chased from Chemicon International (Temecula, CA,
USA). Alexa Fluor 488- and horseradish peroxidase
(HRP)-conjugated goat anti-mouse, goat anti-rabbit,
and donkey anti-goat IgG antibodies were purchased
from Invitrogen (Carlsbad, CA, USA). Cytotoxicity as-
says were performed to assess drug toxicities before the
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Gastric cancer specimens
In this study, 150 cores, including reactive and cance-
rous (different grades and stages) tissues of the stom-
ach, were obtained from a commercial tissue microarray
(BioChain Institute, Inc., Hayward, CA, USA) built for im-
munohistochemical interrogation. AGS-derived gastric
nodules in BALB/c mice were accordingly arrayed [67].
For animal studies, 6- to 8-week-old male wild-type
BALB/c mice were purchased from Jackson Laboratory
(Bar Harbor, ME, USA) and fed standard laboratory food
in the Laboratory Animal Center of National Cheng Kung
University. The animals were raised and handled ac-
cording to the guidelines established by the National
Science Council, Taiwan. The experimental protocols
adhered to the rules of the Animal Protection Act of
Taiwan and were approved by the Laboratory Animal
Care and Use Committee of National Cheng Kung
University.
Cell lines and cell culture
AGS (CRL-1739, ATCC; derived from a biopsy specimen
of an untreated human gastric adenocarcinoma harbor-
ing KRAS, PIK3CA, CDH1, and CTNNB1 mutations),
metastatic MKN45 (JCRB0254, The RIKEN Cell Bank,
Japan; established from a poorly differentiated adenocar-
cinoma of the medullary type from the stomach of a 62-
year-old woman bearing an E-cadherin mutation), and
SNU-1 human gastric adenocarcinoma cells (CRL-5971,
ATCC; derived from a metastatic ascites site of a poorly
differentiated primary stomach carcinoma harboring
KRAS and MLH1 mutations), and GES-1 gastric epithe-
lial immortalized cells, kindly provided by Dr. Pei-Jung
Lu, National Cheng Kung University, were routinely
grown in plastic cell culture dishes in Ham’s F-12 nutri-
ent mixture, DMEM, or RPMI 1640 (F-12, RPMI; Invi-
trogen Life Technologies, Rockville, MD, USA) with
L-glutamine and 15 mM HEPES supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Invitrogen Life
Technologies), 50 units of penicillin, and 50 μg/mL of
streptomycin and maintained in a humidified atmos-
phere with 5% CO2 and 95% air.
Immunohistochemical/immunocytochemical staining
Tissue blocks were fixed overnight at 4°C with 4% neutral
buffered paraformaldehyde solution, dehydrated, cleared
with HistoClear II (National Diagnostics, Atlanta, GA,
USA), and embedded in wax. For immunohistochemical
staining, tissue sections were deparaffinized, rehydrated,
incubated with 3% H2O2 in methanol for 15 min, and sub-
jected to heat-induced antigen retrieval by boiling for
10 min in 0.01 M citric acid. For immunocytochemicalstaining, cells were fixed in 3.7% formaldehyde in PBS for
10 min. After washing twice with PBS, the tissue sections
and cells were mixed with primary antibodies in antibody
diluents (Dako Corporation, Carpinteria, CA, USA) and
incubated overnight at 4°C. The following day, samples
were washed with PBS and incubated with or without
HRP- or fluorescence-labeled secondary antibodies at
room temperature for 1 h. For immunohistochemistry,
antibodies against ILK, Ki-67, pNF-κB, NF-κB, and
pERK1/2 were used. HRP-reactive sections were washed
with PBS, developed with an AEC substrate, counter-
stained with hematoxylin, and visualized using a micro-
scope (IX71; Olympus, Tokyo, Japan). For confocal
microscopy, DAPI (5 μg/mL) was used for nuclear stain-
ing. The sections were then visualized using a confocal
laser scanning microscope (Digital Eclipse C1si-ready;
Nikon, Tokyo, Japan). We alternatively used the Tissue-
FAXS system (TissueGnostics, Vienna, Austria) to analyze
the immunostaining of the tissues. In HistoQuest software
(TissueGnostics, Tarzana, CA, USA), we plotted the X
and Y axes for the expression of the indicated proteins.
Therefore, the upper-right region of dot-plot shows
double-positive expression but not coexpression. The
stained tissue microarray slides were digitized using the
TissueFAXS system. HistoQuest software was used for
detecting and quantifying stained regions. Two markers,
the AEC master marker (ILK, pNF-κB, or Ki-67) and the
hematoxylin non-master marker, were analyzed and
calculated.
Cell viability and cytotoxicity assays
To measure cell growth, cell viability was determined
using a colorimetric assay (Cell Counting Kit-8; Dojindo
Molecular Technologies, Kumamoto, Japan) according
to the manufacturer’s instructions. A microplate reader
(SpectraMax 340PC; Molecular Devices Corporation,
Sunnyvale, CA, USA) was used to measure the absorb-
ance at 450 nm, and the data were analyzed using Soft-
max Pro software (Molecular Devices Corporation). The
relative growth rate was calculated by normalization
to the control group. To evaluate cell damage, lactate
dehydrogenase (LDH) activity was determined using a
colorimetric assay (Cytotoxicity Detection Kit; Roche
Diagnostics, Lewes, UK) according to the manufacturer’s
instructions. Aliquots of culture media were transferred
to 96-well microplates. SpectraMax 340PC was used to
measure the absorbance at 620 nm with a reference
wavelength of 450 nm, and the data were analyzed using
Softmax Pro software.
Western blotting
Harvested cells were lysed in a buffer containing 1% Tri-
ton X-100, 50 mM Tris (pH 7.5), 10 mM EDTA, 0.02%
NaN3, and a protease inhibitor cocktail (Roche Boehringer
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freeze–thaw cycle, cell lysates were centrifuged at
10,000 × g at 4°C for 20 min. The lysates were boiled in
a sample buffer for 5 min. Proteins were then subjected
to SDS-PAGE and transferred to PVDF membranes
(Millipore, Billerica, MA, USA) using a semi-dry elec-
troblotting system. After blocking with 5% skim milk in
PBS, the membranes were incubated overnight with a
1:1,000 dilution of primary antibodies at 4°C. The
membranes were then washed with 0.05% PBS-Tween
20 and incubated with a 1:5,000 dilution of HRP-
conjugated secondary antibody at room temperature
for 1 h. After washing, the membranes were soaked in
ECL solution (PerkinElmer Life and Analytical Sciences,
Inc., Boston, MA, USA) for 1 min and exposed to an X-
ray film (BioMax; Eastman Kodak, Rochester, NY, USA).
The relative signal intensity was quantified using ImageJ
software (version 1.41o; W. Rasband, National Institutes
of Health, Bethesda, MD, USA). The changes in the ratio
of proteins compared with the normalized value of un-
treated cells (indicated protein/β-actin or phosphory-
lated protein/total protein/β-actin) are also determined.
One set of representative data obtained from three inde-
pendent experiments is shown and the data shown as the
mean ± SD values from three independent experiments
(Additional file 15: Figure S14).
Lentiviral-based RNAi transfection
Protein expression was downregulated using lentiviral-
based short hairpin RNA (shRNA) targeting the indi-
cated sequences of the different genes, as summarized in
Additional file 16: Table S1. Luciferase shRNA (shLuc)
was used as a negative control. shRNA clones were ob-
tained from the National RNAi Core Facility, Institute
of Molecular Biology and Genomic Research Center,
Academia Sinica, Taipei, Taiwan. Lentiviruses were pro-
duced by the RNAi Core Facility, National Cheng Kung
University. Cells were transduced by lentiviruses with an
appropriate multiplicity of infection in complete growth
medium supplemented with polybrene (Sigma–Aldrich).
After transduction for 24 h and puromycin (Calbiochem,
San Diego, CA, USA) selection for 3 days, protein ex-
pression was monitored by western blotting. IQGAP1
expression was silenced using the commercial siRNA
IQGAP1-HSS113014, containing the following siRNA
target sequences: 5′-UUUAGCUGCAGGAAUCUGUA
GGGCC-3′ and 5′-GGCCCUACAGAUUCCUGCAGC
UAAA-3′ (Invitrogen). Transfection was performed by
electroporation by using a pipette-type microporator
(Microporator system; Digital Bio Technology, Suwon,
Korea). After transfection, cells were incubated for 18 h in
RPMI 1640 at 37°C before infection. A nonspecific scram-
bled siRNA (Stealth RNAi™ siRNA Negative Control Kit,
12935–100; Invitrogen) was used as the negative control.Electrophoretic mobility shift assays
Cells were incubated in 300 μL buffer A [10 mM HEPES
(pH 7.9), 1.5 mM magnesium chloride, 10 mM potas-
sium chloride, 0.5 mM phenylmethylsulfonyl fluoride,
0.5 mM dithiothreitol, 2 μg/mL leupeptin, 10 μg/mL
aprotinin, 50 mM sodium fluoride, and 1 mM sodium
orthovanadate] on ice for 10 min and gently shaken for
10 s. The pellet containing crude nuclei was collected
using centrifugation at 12,000 × g for 10 s, resuspended
in 30 μl buffer C [20 mM HEPES (pH 7.9), 25% glycerol,
420 mM sodium chloride, 1.5 mM magnesium chloride,
0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride,
0.5 mM dithiothreitol, 2 μg/mL leupeptin, 10 μg/mL
aprotinin, 50 mM sodium fluoride, and 1 mM sodium
orthovanadate] by vortexing for 15 s, followed by incu-
bation on ice for 20 min. After centrifuging the cells at
12,000 × g for 2 min, the supernatant containing nuclear
proteins was collected, quantified (BCA Protein Assay
Reagent; Pierce Biotechnology, Inc., Rockford, IL, USA),
and stored in aliquots at −70°C. The electrophoretic mo-
bility shift assay (EMSA) used the following oligonucleo-
tides as probes: NF-κB (f ): 5′-CAA ATG TGG GAT
TTT CCC ATG AGT; NF-κB (r): 5′-GAC TCA TGG
GAA AAT CCC ACA TTT G. The forward and reverse
oligonucleotides (30 pmol) were placed in 23 μL of DNA
polymerase buffer (Klenow 1X; Promega, Madison, WI,
USA), heated at 94°C for 2 min, and annealed at room
temperature for 30 min. The annealed double-stranded
oligonucleotides were end-labeled using a fill-in reaction
with Klenow polymerase. One unit of Klenow and 40 μCi
of [32P] dCTP (PerkinElmer Life and Analytical Sciences,
Inc.) were added to the annealed oligonucleotides, and the
mixture was incubated at 30°C for 15 min. The labeled oli-
gonucleotides were purified using G-50 columns (Sepha-
dex; PerkinElmer Life and Analytical Sciences, Inc.). The
DNA-binding reaction was performed at 4°C for 30 min
in a mixture containing 3 μg of nuclear extract, 10 mM
Tris–HCl [pH 7.5], 50 mM sodium chloride, 0.5 mM di-
thiothreitol, 0.5 mM EDTA, 1 mM magnesium chloride,
4% glycerol, 0.05 μg poly (dI-dC)-poly (dI-dC) (PerkinEl-
mer Life and Analytical Sciences, Inc.), and 2 × 104 cpm
32P-labeled double-stranded oligonucleotides. Samples
were analyzed on a 4% polyacrylamide gel (acrylamide/
bis-acrylamide 29:1 in 0.5× Tris-borate–EDTA buffer) at
10 V/cm for 2 h. The gel was dried and analyzed using a
quantitative autoradiography densitometer.
Luciferase reporter assay
To analyze NF-κB promoter activity by a luciferase re-
porter assay, transient transfection was performed using
the GeneJammer transfection reagent (Stratagene, La
Jolla, CA, USA). In short, cells were cotransfected with
0.2 μg of an NF-κB-promoter-driven firefly luciferase re-
porter and 0.01 μg of a Renilla luciferase-expressing
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fection, the cells were lysed and harvested for firefly and
Renilla luciferase using the Dual-Glo luciferase assay sys-
tem (Promega). For each lysate, firefly luciferase activity
was normalized to Renilla luciferase activity to assess
transfection efficiencies.Ras pull-down assay
Ras activation assays were performed according to the
affinity precipitation protocol provided by the manufac-
turer (Ras Activation Assay Kit 28820; Single Oak Drive,
Temecula, CA, USA). Cell lysates were incubated with
Raf-1 RBD for 45 min at 4°C and centrifuged to pellet
agarose beads. The agarose beads were washed, and the
pellets were resuspended in 2× Laemmli sample buffer
and boiled for 5 min. The supernatant was collected,
and cellular proteins were resolved by SDS-PAGE and
analyzed by immunoblotting.Coimmunoprecipitation
For coimmunoprecipitation, 100 μg cell lysate from cells
was incubated overnight at 4°C with 5 μg protein G
(Amersham Biosciences, Uppsala, Sweden) and 2 μg of
antibodies. The expression of interacting proteins was
determined by Western blotting.Transfection
Transient transfection was performed using an MP-100
Microporator (Digital Biotechnology) according to the
manufacturer’s instructions for optimization and usage.
The plasmid expressing EGFP-PTEN (ID NM_000314;
Plasmid 13039) and its control pcDNA3-EGFP (Plasmid
13031); pWZL-Neo-Myr-Flag-ILK (ID NM 004517; Plas-
mid 20505) and its control pWZL-Neo-Myr-Flag-Dest
(Plasmid 15300); and wild-type EGFR (Plasmid 11011),
EGFR dominant-negative mutant (EGFRVIII) (Plasmid
11015) and their control vector pBABE-puro (Plasmid
1764) were purchased from Addgene (Cambridge, MA,
USA). ILK dominant-negative mutant (ILKA262V) (ID
NM_004517) was purchased from OriGene Technolo-
gies, Inc. (Rockville, MD, USA). Three FLAG-tagged
recombinant ILK proteins, full-length ILK1–452, N-
terminal truncated ILK171–452, and C-terminal truncated
ILK1–171, were constructed as described previously [18].
After transfection, the cells were cultured for 24 h before
the experiments.PI3K activity assay
A PIP3 Mass ELISA (K-2500 s, Echelon Biosciences, Salt
Lake City, UT, USA) was performed to detect PI3K activ-
ity in cells according to the manufacturer’s instructions.Wound healing assay
For cell migration assays, the confluent monolayers of
cells were wounded by scraping a pipette tip across the
monolayer. The cells were washed with PBS and incu-
bated with appropriate media. Images at 100× magnifica-
tion were taken at wounding and 12 h later by using a
microscope (IX71; Olympus). Cell migration was assessed
using ImageJ software and was reported as the number of
cells that migrated into the scraped region.
Apoptosis assay
Apoptosis was assessed using nuclear propidium iodide
(PI; Sigma–Aldrich) staining and flow cytometry (FACS-
Calibur; Becton Dickinson, San Jose, CA, USA) with ex-
citation at 488 nm and emission in the FL2 channel
(565–610 nm). Samples were analyzed using CellQuest
Pro 4.0.2 software (Becton Dickinson), and quantifica-
tion was performed using WinMDI 2.8 software (The
Scripps Institute, La Jolla, CA, USA). Apoptosis levels
were reported as the percentages of sub-G1 phase cells.
Statistical analyses
Values were expressed as mean ± standard deviation
(SD). Significant differences between groups were assessed
using one-way ANOVA followed by Dunnett’s post hoc
test as appropriate, Student’s t test, or analysis of variance.
Analyses were performed using GraphPad Prism 4 soft-
ware (GraphPad Software Inc., La Jolla, CA, USA). After
the densities of the detected proteins were quantified
using HistoQuest software, logistic regression analysis of
the graded expression of ILK, phosphorylated NF-κB
Ser536, and Ki-67 in 93 gastric cancer specimens tested
was performed. After the AEC-based immunohistochem-
istry assay, no AEC staining was considered negative,
<25% staining was considered grade 1, between 25% and
50% staining was considered grade 2, and >50% staining
was considered grade 3. Data analysis was performed
using multinomial logistic regression and the pseudo R-
squared test in GraphPad Prism 4 software (GraphPad
Software Inc.). The exact P-values are listed in the corre-
sponding figure legends. Statistical significance was set at
P <0.05.
Supplemental materials and methods
The additional information was also attached (Additional
file 1: Supplemental materials and methods).
Additional files
Additional file 1: Supplemental materials and methods.
Additional file 2: Figure S1. Expression of ILK in gastric tumors. The
representative AEC-based immunohistochemical staining of ILK and Ki-67 in
2 gastric tumor patients. Hematoxylin is used for nuclear counterstaining.
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activation. (A) WST-8-based assay showed cell growth hi gastric cancer
cell lines AGS, SNU-l, MKN45, and GES-l compared with the status at
Day 0. Western blotting (B) and immunostaining (C) showed ILK expression.
β-actin was used as an internal control. The mean fluorescent intensity (MEl)
per tested cell is also shown. (B) Western blotting showed ILK expression in
shLuc- and shILK-transfected A549 and Hl975 human lung adenocarcinoma
cells, HK2 human renal proximal tubular epithelial cells, and THP 1 human
acute monocytic leukemia cells. β-actin was used as an internal control.
(E) Silencing ILK retarded cell growth. (F) shLuc- or shILK-transfected AGS
cells were cultured for 14 days, and colony formation was manually
counted. PI staining followed by flow cytometry analysis showed the cell
cycle in shLuc- or shILK-transfected AGS cells treated with vinorelbine (VNR.
1 μM) (G) and in AGS cells treated with T315 (H) for 24 h compared with
DMSO-treated groups. The percentages of cells at the indicated phases are
shown. (I) Immunostaining showing the nuclear translocation of NF-κB.
(J) NF-κB activation in shLuc- and shILK-transfected cells was determined.
For cell growth, cell cycle, and luciferase activity, data are the means ± SD
from three individual experiments. tp < 0.001 compared with Day 0 or
relative control. #P <0.05 and ##P < 0.01 compared with shLuc.
Additional file 4: Figure S3. Expression of ILK, phosphorylated
NF-κB, and Ki-67 in. gastric tumors. (A) The representative AEC-based
immunohistochemical staining showed the expression of ILK,
phosphorylated NF-κB at Ser536, and Ki-67 in a gastric tissue array
containing 150 cases. Hematoxylin is used for nuclear counterstaining.
An example of triple-positive staining is shown. (B) Ninety-three of
150 cases of gastric cancer specimens were statistically analyzed for
the graded expression (Grade I, <25%; Grade II, 25-50%; Grade III, >50% of
observed region) of these proteins by a logistic regression analysis.
Additional file 5: Figure S4. ILK facilitates ERK1/2 signaling. (A) The
Human Phospho-Kinase Array (Catalog # ARY003B, R & D systems) was
performed to detect the phosphorylation of 43 kinases and 2 related total
proteins in AGS and MKN45 cells. The mean raw density is shown as the
mean data of changed kinases and the positive controls as indicated.
Western blotting showed the expression of the indicated proteins in
shLuc- and shILK-transfected cells (B), and PD98059-treated AGS cells
(C), and β-actin was used as an internal control. (D) Cell cycle analysis
showed the effects of PD98059 treatment for 48 h. (E) Western blotting
showed the expression of IQGAP1, IQGAP2, and IQGAP3 in AGS, MKN45,
and shLuc- or shILK-transfected AGS cells. In shLuc- or shIQGAP3-transfected
AGS cells, the expression of the indicated proteins (F), NF-κB activation
(G), and cell growth (H) were also determined. For cell cycle, luciferase
activity, and proliferation assay, data are the means ± SD from three individual
experiments. NS, not significant. Regular triangle, increased expression;
inverted triangle, decreased expression.
Additional file 6: Figure S5. Expression of ILK, IQGAP1, and Ras in AGS
cells. The representative fluorescence-based immunohistochemical staining
of ILK (green), IQGAP1 (red), and Ras (red) in AGS cells. DAPI (blue) is used for
nuclear counterstaining.
Additional file 7: Figure S6. Expression of integrins in AGS and MKN45
cells. One representative histogram of immunostaining followed by flow
cytometry analysis shows the expression of β1 and β3 integrins and the
active form of β1 integrin in AGS and MKN45 cells. 2°Ab, secondary
antibody.
Additional file 8: Figure S7. ILK facilitates ERK1/2 phosphorylation. AGS
cells were treated with PD98059, LY294002, T315, or Ras inhibitor FTI-277
for the indicated times. Western blotting showed the expression of the
indicated proteins. β-actin was used as an internal control.
Additional file 9: Figure S8. AKT is not required for ILK stabilization in
AGS cells. Western blotting showed the expression of ILK and phosphorylated
AKT at Ser473 (pAKT S) in AGS cells treated with LY294002 and AKT inhibitor
5-(2-Benzothiazolyl)-3-ethyl-2-[2-(methylphenylamino) ethenyl]-1-
phenyl-1H-benzimidazoli um iodide (AKTi, 2.5 μM). β-actin was used as
an internal control. Inverted triangle, decreased expression.
Additional file 10: Figure S9. HSP90 signaling regulates ILK stabilization
and ERK1/2/NF-κB signaling. Western blotting shows the expression of the
indicated proteins in AGS cells treated with 17-AAG (A) and SAHA in the
presence of MG132 (C). β-actin was used as an internal control. (B) Reporterassay detected NF-κB activation in AGS cells treated with SAHA (5 μM) for
24 h. Data are the means ± SD from three individual experiments. *P < 0.05
compared with DMSO. Regular triangle, increased expression; inverted
triangle, decreased expression.
Additional file 11: Figure S10. MG132 treatment reverses ILK expression
to facilitate ERK1/2/NFκB activation in MKN45 cells. Western blotting showed
ILK expression and phosphorylation of MEK1/2 and ERK1/2 in MKN45 cells
treated with MG132. β-actin was used as an internal control. Regular triangle,
increased expression.
Additional file 12: Figure S11. Signaling of PI3K/HSP90/CHIP/ILK/ERK1/
2/NF-κB determines cell migration. Migration activity was tested in AGS,
MKN45, shILK- or siIQGAP1-transfected AGS cells (A), LY294002 (25 μM),
17-AAG (0.2 μM), T315 (2.5 μM), 9 PD98059 (50 μM), or CAPE (25 μg/ml)-
treated AGS cells (B), and shLuc- or shCHIP-transfected AGS cells treated
with LY294002 (25 μM) and 17-AAG (0.2 μM) (C) for 12 h. shLuc, control
siRNA, or DMSO were used as the negative controls. A representative
image in the observed field is shown. The numbers of migrated cells in
the observed field are shown. (D) PI staining followed by flow cytometry
analysis showed 5-FU- or cisplatin-induced apoptosis for 2 days in AGS or
MKN45 cells pre-treated with T315 for 0.5 h. DMSO were used as the
negative controls. Data are the means ± SD from three individual experiments.
*P< 0.05, **P< 0.01 and ***P< 0.001 compared with relative control. #P< 0.05,
##P< 0.01, and ###P< 0.001 compared with relative control.
Additional file 13: Figure S12. ILK individually determines activation of
AKT and ERK1/2 in response to different stimuli. Western blotting showed
the phosphorylation of AKT at Ser473 (pAKT S) and ERK1/2 at Tyr202/
Thr204 (pERK1/2) in shLuc- or shILK-transfected A549 or MKN45 cells with
EGF (10 ng/ml) (A) and hydrogen peroxide (H2O2, 10 μM) (B) treatment
for 1 h or Helicobater pylori (H. pylori, MOI = 10) infection for 6 h (C). β-actin
was used as an internal control. Regular triangle, increased expression;
inverted triangle, decreased expression.
Additional file 14: Figure S13. PAK1 is regulated for c-Raf/ERK1/2
signaling, NF-κB activation and cell proliferation but not for ILK stabilization.
AGS cells were treated with LY294002 for 24 h (A) and transfected with
shLuc and shPAK1 clones #1 and #2 (B). Western blotting showed the
expression of the indicated proteins. β-actin was used as an internal
control. The activation of NF-κB (C) and cell proliferation (D) in shLuc- and
shPAK1-transfected AGS cells were determined. For luciferase activity and cell
proliferation, data are the means ± SD from three individual experiments.
**P < 0.01 compared with shLuc. Inverted triangle, decreased expression.
Additional file 15: Figure S14. Quantification of protein expression.
For the immunoblots 10 and immunoprecipitation data in the indicated
figures, the relative signal intensity was quantified using ImageJ software.
The changes in the ratio of proteins compared with the normalized value
of untreated cells (indicated protein/β-actin or phosphorylated protein/
total protein/β-actin) are also determined. The data shown as the mean ±
SD values from three independent experiments. *P < 0.05, **P < 0.01, and
***P < 0.001 compared with the relative controls. #P < 0.05, ##P < 0.01, and
###P < 0.001 compared with the indicated controls. ns, not significant.
Additional file 16: Table S1. Target sequences of shRNAs used in this
study.Abbreviations
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